Drug development for rare cancers presents distinct challenges. An #AACR26 panel discussion moderated by E. Dianne Pulte of the FDA will explore opportunities in trial design and real-world data that can mitigate these difficulties.
https://
brnw.ch/21x1IFz
#AACRSciencePolicy